Article by Yippee-Ki-Yay

Terveystalo: A good health-sector investment on the stock market

Buy signal | Free publication | 16 Nov 2026

Terveystalo at €6.13: the Finnish private healthcare giant that makes teeth grind (or smile)?

Terveystalo is Finland’s leading private healthcare player. Think medical centers, dental services, corporate health contracts and a highly practical positioning in a country where the public system often struggles with waiting times. The model is straightforward and cash-generative: patient volume + B2B contracts + operational efficiency. The share currently trades around €6.13. Is this a genuine opportunity or a classic value trap? Let’s break it down.

Detailed Financial Analysis (Score out of 5)

Revenue (Growth and momentum) – 3/5

2025 revenue comes in at €1,279 million, a slight decline versus €1,340 million in 2024. Over the longer term the company has grown from €986 million in 2020, but recent momentum is soft. Consensus expects a gradual recovery (€1,431 million in 2027, €1,513 million in 2028). Not a rocket ship — more of a tanker steadily moving forward. Score just above average.

Net Income (Overall profitability) – 4/5

After a rough patch in 2023 (-€42 million), net profit has rebounded nicely: €72 million in 2024 and €93 million in 2025. Forecasts remain positive (€76 million in 2026, €106 million in 2027, €119 million in 2028). Operating profitability is improving and EBITDA holds up well. Solid recovery story.

Debt levels (Financial strength and debt structure) – 2.5/5

Total debt sits around €580 million at the end of 2025, with net debt even higher according to consensus. Equity is roughly €584 million. The debt-to-equity ratio remains elevated and forecasts show net debt stabilizing or rising slightly before declining. No liquidity crisis thanks to solid operating cash flow (€206 million in 2025), but the balance sheet is still heavy. Not in the comfort zone.

Return on Equity (ROE) – 3.5/5

Current ROE stands around 19.7% according to forecasts. It is expected to dip in 2026 (around 13.2%) before climbing back toward 16-17%. Acceptable for the sector, but not outstanding. Shareholder value creation is present without being spectacular.

Market performance (Current valuation) – 4/5

Trailing PE sits at 13.6 with a forward PE of 6.9. Price/Sales is low. At €6.13 the market is clearly not euphoric. Consensus leans toward “Buy” / “Hold” with an upward bias on forward multiples. Attractive valuation if the forecasts materialize.

Overall average: 3.4/5

A decent-quality company — not a pure growth gem, but a defensive player showing a clear return to profitability and a valuation that leaves room for upside.

Outlook & Forecasts (2027–2028)

Consensus sees net income rising toward €106-119 million in 2027-2028, EPS progressing and revenue crossing the €1.5 billion mark. EBITDA and EBIT follow the same upward trajectory. The current consensus remains constructive (leaning toward the buy side).

Price targets (reasoned estimates):

  • End of 2026: €7.20 – €7.80 zone if the forward PE normalizes around 9-10x and net profit holds.
  • 2028 horizon: €8.50 – €9.50 in the base case (earnings growth + slightly more generous multiple). Real upside, but not explosive. Main risks remain the debt load and any slowdown in the Finnish economy.

Sector Analysis (Strengths / Weaknesses)

Strengths

  • Structural demand growth (aging population + pressure on public healthcare)
  • Relative pricing power on private and B2B services
  • Barriers to entry (network, reputation, regulation)
  • Generally predictable cash-flow profile

Weaknesses

  • Heavy exposure to a single market (Finland)
  • Pressure on wage costs and regulatory requirements
  • Competition from the public system and other private players
  • Sensitivity to economic cycles (corporate contracts)

Allocation Strategy

Total budget of €10,000 to allocate across 10 listed companies. In pure “advice between mates” mode (this is not official financial advice — do whatever you want): I would put €900 to €1,000 into Terveystalo.

Why? Valuation is not expensive, the return to profitability is visible, and the sector is defensive. This is not the high-octane growth name in your portfolio — it’s the solid guy that stabilizes things. You don’t get wiped out if it underperforms, and you capture the upside if forecasts come through. The rest of the cash goes into more dynamic or deeper-value ideas depending on your style.

Conclusion

Terveystalo is not the next Tesla of healthcare. It is a mature, somewhat leveraged player that is emerging from a difficult year and regaining color. At €6.13 the risk/reward looks reasonable for a defensive profile.

Honest verdict: yes, you can buy, but as a secondary position rather than a core holding. Take a measured stake, monitor debt evolution and upcoming results, and let time do its work. If you’re chasing pure double-digit growth, look elsewhere. If you want a slice of Finnish private healthcare at a reasonable price with re-rating potential, it’s playable.

Your call. And remember: markets love to make you doubt right before they move higher.

  • Signal : Buy
  • Budget/Investment : Medium
  • Reinforcement required : No
  • Exposure : Medium
  • Horizon : 2 to 3 years
  • Potential profitability : +30% to +46%
  • Ref. ISIN code : FI4000252127